Evogene (EVGN) Enterprise Value (2012 - 2026)
Evogene (EVGN) posted Enterprise Value of -$8511.0 for Q1 2026, up 99.05% sequentially from -$899000.0 in Q4 2025, and up 99.91% YoY from -$4257.3 in Q1 2025.
Evogene (EVGN) Enterprise Value (2012 - 2026) Analysis & Trends
Evogene has reported Enterprise Value for 15 years, with the latest figure at -$8511.0 in Q1 2026.
- Quarterly Enterprise Value rose 99.91% year-over-year to -$8511.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8511.0 (up 99.91% YoY) and the FY2025 annual result came in at -$899000.0, down 191.92% from the prior year.
- Enterprise Value grew to -$8511.0 in Q1 2026 per EVGN's latest filing, from -$899000.0 in the prior quarter.
- Over five years, Enterprise Value peaked at $4.2 million in Q2 2025 and troughed at -$26.8 million in Q1 2022.
- A 5-year average of -$11.8 million and a median of -$14.4 million in 2023 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 204.93% in 2025, down 373.25% in 2025.
- Over 5 years, Enterprise Value stood at -$22.1 million in 2022, then surged by 34.76% to -$14.4 million in 2023, then jumped by 106.78% to $978000.0 in 2024, then plunged by 191.92% to -$899000.0 in 2025, then surged by 99.05% to -$8511.0 in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$8511.0, -$899000.0, and -$16.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -8,511.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,511.00 |
| Dec 31, 2025 | -899,000.00 |
| Sep 30, 2025 | -15.96 Mn |
| Jun 30, 2025 | 4.23 Mn |
| Mar 31, 2025 | -9.85 Mn |
| Dec 31, 2024 | 978,000.00 |
| Sep 30, 2024 | -3.37 Mn |
| Jun 30, 2024 | -4.04 Mn |
| Mar 31, 2024 | -9.52 Mn |
| Dec 31, 2023 | -14.43 Mn |
| Sep 30, 2023 | -19.87 Mn |
| Jun 30, 2023 | -17.05 Mn |
| Mar 31, 2023 | -16.59 Mn |
| Dec 31, 2022 | -22.12 Mn |
| Sep 30, 2022 | -24.14 Mn |
| Jun 30, 2022 | -20.42 Mn |
| Mar 31, 2022 | -26.81 Mn |
| Dec 31, 2021 | -25.56 Mn |
| Sep 30, 2021 | -31.17 Mn |
| Jun 30, 2021 | -34.51 Mn |